Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma.

about

Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma.

Item

http://www.wikidata.org/entity/Q54998752

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Comparison of the algorithms c ...... diffuse large B-cell lymphoma.

@en

Comparison of the algorithms c ...... diffuse large B-cell lymphoma.

@nl

type

Item

label

Comparison of the algorithms c ...... diffuse large B-cell lymphoma.

@en

Comparison of the algorithms c ...... diffuse large B-cell lymphoma.

@nl

prefLabel

Comparison of the algorithms c ...... diffuse large B-cell lymphoma.

@en

Comparison of the algorithms c ...... diffuse large B-cell lymphoma.

@nl

P1476

Comparison of the algorithms c ...... diffuse large B-cell lymphoma.

@en

P2093

Barbara Jezeršek Novaković

http://www.w3.org/2001/XMLSchema#string

Gorana Gašljević

http://www.w3.org/2001/XMLSchema#string

Lučka Boltežar

http://www.w3.org/2001/XMLSchema#string

Maja Pohar Perme

http://www.w3.org/2001/XMLSchema#string

Veronika Kloboves Prevodnik

http://www.w3.org/2001/XMLSchema#string

P2860

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival.

P304

6903-6912

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.8243

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29731865

http://www.w3.org/2001/XMLSchema#string

P932

5921237

http://www.w3.org/2001/XMLSchema#string